Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PT-101 by Merck for Systemic Lupus Erythematosus: Likelihood of Approval
PT-101 is under clinical development by Merck and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
PT-101 by Merck for Ulcerative Colitis: Likelihood of Approval
PT-101 is under clinical development by Merck and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II...
PT-101 by Merck for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
PT-101 is under clinical development by Merck and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Merck's PT-101?
PT-101 is a fusion protein commercialized by Merck, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
PT-101 by Merck for Vitiligo: Likelihood of Approval
PT-101 is under clinical development by Merck and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs...